The Minoxidil Response Test is not approved or cleared for sale by the US FDA.

NOT AVAILABLE FOR COMMERCIAL SALE.

Topical minoxidil is available over-the-counter (OTC) and as such is widely used for the treatment of hair loss; however, following 4-6 months of daily or twice daily application, a significant number of patients do not respond to the drug.  Since hair loss is progressive and is often a manifestation of an underlying condition other than pattern hair loss, identifying patients that are unlikely to respond to topical minoxidil is of great importance.

The Minoxidil Response Test was developed to aid a physician in assessing if a patient is likely not to respond to topical minoxidil treatment for pattern hair loss.

At the Daniel Alain Life Science, we are developing new medical devices and drugs for the treatment of male and female pattern hair loss.  In September 2017, our parent company, Follea International Ltd., submitted a De Novo application for a medical device – the Minoxidil Response test. 

WHAT IS THE MINOXIDIL RESPONSE TEST?

WHAT IS TOPICAL MINOXIDIL?

Topical minoxidil is the only topical drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of Male and Female Pattern Hair Loss. 

Robotic Lab Assistant
Microscope
Experiment
Lab Experiment
Microscope
Petri Dish

IN THE NEWS:

Follea International Ltd., submits an application for a new diagnostic test -

Minoxidil Response Test - to the U.S. Food and Drug Administration

NOT AVAILABLE FOR COMMERCIAL SALE.

 
 
 
 

If you would like to learn more about this initiative and other ground-breaking research, please provide your email address below.

NOTIFY ME

©2017 by Minoxidil Response Test

Daniel Alain - CHINA - GERMANY - USA
Worldwide Headquarters:

520 Newport Center Dr, Suite 300

Newport Beach, CA 92660

Petri Dish